Cefamandole

Summary

Cefamandole (CHEMBL1146) is an approved small-molecule antibacterial drug (ATC J01DC03); indicated across 2 conditions including bacterial infectious disease and osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DC03
• Indications: 2 conditions
• Chemistry: 462.5 Da · C18H18N6O5S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1146
Name	Cefamandole
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	456255
ChEBI	CHEBI:3480
ATC	J01DC03
Molecular formula	C18H18N6O5S2
Molecular weight	462.5
InChIKey	OLVCFLKTBJRLHI-AXAPSJFSSA-N

SMILES: CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)[C@@H](C4=CC=CC=C4)O)SC2)C(=O)O

IUPAC name: (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A cephalosporin compound having (R)-mandelamido and N-methylthiotetrazole side-groups.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Cefamandol, Cefamandole, Cephamandole, COMPOUND 83405, COMPOUND-83405, J01DC03, cefamandole, CEFAMANDOLE

Parent form; salt/anhydrous children: CHEMBL1360024, CHEMBL3230485

Patent coverage: 5,604 distinct patent families (21,886 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Solute carrier family 22 member 6, Organic anion transporter 3, Organic anion transporter 3, Solute carrier family 22 member 11, Progesterone receptor, Peroxisome proliferator-activated receptor gamma, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 8 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC22A6	7.52	Ki	30	nM	CHEMBL_ACT_11002241
SLC22A8	7.34	Ki	46	nM	CHEMBL_ACT_11002248
SLC22A11	5.94	Ki	1140	nM	CHEMBL_ACT_11002315
NR1I2	5.82	AC50	1500	nM	CHEMBL_ACT_25187908
NR1I2	5.75	AC50	1800	nM	CHEMBL_ACT_25223630
PGR	5.41	AC50	3900	nM	CHEMBL_ACT_25221863
PPARG	5.01	AC50	9700	nM	CHEMBL_ACT_25113862

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).